Mesothelioma

Latest News

Data from the phase 2/3 KEYNOTE-483 trial support the CHMP’s recommendation for approving pembrolizumab/chemotherapy in the European Union.

Pembrolizumab/Chemo Earns Positive EU CHMP Opinion in Mesothelioma

November 15th 2024

Data from the phase 2/3 KEYNOTE-483 trial support the CHMP’s recommendation for approving pembrolizumab/chemotherapy in the European Union.

Data from the KEYNOTE-483 trial support the FDA approval of the pembrolizumab-based combination in this pleural mesothelioma population.

FDA Approves Pembrolizumab/Chemo in Unresectable Pleural Mesothelioma

By Russ Conroy

September 17th 2024

Data from the phase 2 NIPU trial support the FDA’s fast track designation for UV1 in combination with nivolumab and ipilimumab as a treatment for those with unresectable pleural malignant mesothelioma.

FDA Grants Fast Track Designation to UV1 Vaccine Combo in Unresectable Mesothelioma

By Russ Conroy

February 6th 2024

The accepted new drug application is for Pemrydi RTU, a ready-to-use injectable that requires no reconstitution, dilution, or refrigeration.

FDA Accepts NDA for Pemetrexed Injection in NSCLC, Mesothelioma

By Nicholas Wrigley

June 16th 2023

SynKIR-110, which received fast track designation from the FDA, is currently under investigation as treatment for patients with mesothelioma in the phase 1 STAR-101 trial.

FDA Grants Fast Track Designation to Novel T-Cell Therapy in Mesothelioma

By Russ Conroy

April 10th 2023

Latest CME Events & Activities

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

22nd Annual Winter Lung Cancer Conference®

January 31, 2025 - February 2, 2025

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

26th Annual International Lung Cancer Congress®

July 25-26, 2025

More News

Gemcitabine Plus Ramucirumab Improves Overall Survival in Malignant Mesothelioma

Ariana Pelosci

October 6th 2021

Patients who were treated with ramucirumab plus gemcitabine experienced improved overall survival compared with patients treated with gemcitabine plus placebo.

Patients with resectable pleural mesothelioma underwent safe and effective treatment with the triplet combination of neoadjuvant cisplatin, pemetrexed, and atezolizumab from the ongoing S1619 trial.

Neoadjuvant Cisplatin, Pemetrexed, and Atezolizumab Combination Safe and Effective for Resectable Pleural Mesothelioma

Lindsay Fischer

September 13th 2021

Patients with resectable pleural mesothelioma underwent safe and effective treatment with the triplet combination of neoadjuvant cisplatin, pemetrexed, and atezolizumab from the ongoing S1619 trial.

Extrapleural Pneumonectomy After Radiation Produced Durable Survival and Was Considered Safe for Malignant Pleural Mesothelioma

Matthew Fowler

February 26th 2021

Data published in The Lancet Oncology investigating patients with malignant pleural mesothelioma determined that surgery for mesothelioma after radiotherapy, or SMART, can produce positive early- and long-term effects.

FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma

Kristie L. Kahl

October 2nd 2020

The agency approved the first and only immunotherapy treatment as a first-line therapy for adult patients with unresectable malignant pleural mesothelioma.

Nivolumab Plus Ipilimumab Improves OS in Malignant Pleural Mesothelioma

Matthew Fowler

August 10th 2020

Data from the phase 3 CheckMate-743 trial showed a statistically significant overall survival benefit for patients with previously untreated, unresectable malignant pleural mesothelioma when treated with nivolumab plus ipilimumab.